STOCK TITAN
  1. Home
  2. Sec-filings
  3. CATX
  4. [8-K] Perspective Therapeutics, Inc. Reports Material Event

Perspective Therapeutics (NYSE: CATX) grows cash to $237M while advancing Phase 3-ready pipeline

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. reported second quarter 2026 results and provided a broad pipeline and manufacturing update. The company is advancing bamzireotide navoxetan (VMT-α-NET) toward a planned Phase 3 study in SSTR2-positive neuroendocrine tumors, targeting clinical site activation around year-end 2026, subject to regulatory feedback and protocol finalization. VMT01 in MC1R-positive melanoma and PSV359 in FAP-α-positive solid tumors continue in Phase 1/2a development, while PSV594 remains in pre-IND work. An updated VMT-α-NET data set will be presented at ESMO on October 23, 2026.

The company is expanding its 212Pb-based radiopharmaceutical manufacturing network, expecting its Chicago metro site to complete construction in early 2027 and its Los Angeles metro site in the second half of 2027, for four regional sites by year-end 2027. Cash, cash equivalents, and short-term investments totaled $237 million as of June 30, 2026, up from $145 million at December 31, 2025, and are expected to fund planned clinical milestones and operational investments into late 2027.

For the quarter ended June 30, 2026, research and development expenses were $21.5 million versus $16.6 million a year earlier, and general and administrative expenses were $7.8 million versus $7.7 million. Net loss was $26.8 million, or $0.22 per share, compared with a net loss of $21.5 million, or $0.29 per share, in the prior-year quarter. Total assets were $392.0 million and stockholders’ equity was $323.9 million as of June 30, 2026. The company also appointed Paul Lyne, Ph.D. as Chief Science Officer.

Positive

  • $237 million in cash, cash equivalents, and short-term investments as of June 30, 2026, with runway expected to fund planned clinical milestones and operations into late 2027.
  • Advancing bamzireotide navoxetan (VMT-α-NET) toward a Phase 3 study in SSTR2-positive neuroendocrine tumors, with site activation targeted around year-end 2026, subject to regulatory feedback.

Negative

  • Quarterly net loss increased to $26.8 million from $21.5 million year over year, driven by higher operating expenses, particularly research and development.
  • Research and development expenses rose to $21.5 million from $16.6 million for the quarter, contributing to a larger overall operating loss.

Filing Explained

At June 30, 2026, Perspective Therapeutics reported 114,086,092 issued common shares, compared with 74,337,990 at December 31, 2025; the filing does not provide transaction-level mechanics explaining the change, so its ownership effect cannot be sized from this disclosure alone.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Cash, cash equivalents and short-term investments $237 million As of June 30, 2026; compared with approximately $145 million as of December 31, 2025
Research and development expenses $21.5 million Three months ended June 30, 2026; $16.6 million for the three months ended June 30, 2025
General and administrative expenses $7.8 million Three months ended June 30, 2026; $7.7 million for the three months ended June 30, 2025
Net loss $26.8 million Three months ended June 30, 2026; $21.5 million for the three months ended June 30, 2025
Basic and diluted loss per share $0.22 Quarter ended June 30, 2026; $0.29 loss per share for the quarter ended June 30, 2025
Total assets $392,025 Total assets as of June 30, 2026; dollars in thousands
Total stockholders’ equity $323,863 Stockholders’ equity as of June 30, 2026; dollars in thousands
Patients treated with VMT-α-NET 76 NETs patients and 1 meningioma patient Treated across four cohorts plus one meningioma patient as of July 31, 2026
theranostic medical
"This "theranostic" approach enables visualization of the specific tumor"
A theranostic is a single medical approach or agent that combines diagnosis and treatment—using a test or imaging step to find patients likely to benefit, then delivering a targeted therapy tied to that same marker. For investors, theranostics can speed development, lower the chance of failed trials and concentrate sales on the right patients, like a smart key that both locates the correct lock and opens it, potentially improving clinical and commercial success.
SSTR2-positive neuroendocrine tumors medical
"bamzireotide navoxetan (VMT-α-NET) in SSTR2-positive neuroendocrine tumors (NETs)"
Phase 3 study medical
"Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors"
A phase 3 study is the large-scale clinical trial that tests whether a new drug or medical treatment actually works and is safe in a broad group of patients, typically after earlier smaller tests. Investors watch these studies like a final dress rehearsal because their successful completion is often required for regulatory approval and market access; positive or negative results can sharply change a company’s future sales prospects and stock value.
212Pb medical
"The Company has proprietary technology that utilizes the alpha-generating isotope 212Pb"
212Pb is a radioactive form of the metal lead used as a delivery vehicle in certain cancer treatments; it decays to produce short-range, high-energy particles that can destroy tumor cells near where it lodges. For investors, it matters because drugs using 212Pb combine scientific promise with regulatory, manufacturing and safety challenges—similar to a precision-guided tool that can be powerful but costly and complex to develop and commercialize.
grant revenue financial
"Grant revenue $ 81 $ 290 $ 157 $ 632"
Grant revenue is money an organization receives from governments, foundations, or other institutions to fund a specific project or purpose rather than from sales of products or services. For investors it matters because these funds can boost cash flow and support research, development or operations without diluting ownership, but they may be time-limited, restricted in use, or unpredictable—like a one-time gift that helps but may not repeat.
additional paid-in capital financial
"Additional paid-in capital 711,785 541,687"
Amount of money shareholders have paid to a company for shares that is above the stock’s nominal or par value; think of it as the extra premium paid when a group buys a ticket that has a low listed price. It matters to investors because it represents permanent capital on the balance sheet that can cushion losses, affect book value per share and indicate how much fresh cash equity holders have contributed beyond the minimum share value.
Net loss $26.8 million Increased from $21.5 million for the quarter ended June 30, 2025
Research and development expenses $21.5 million Increased from $16.6 million for the quarter ended June 30, 2025
General and administrative expenses $7.8 million Compared with $7.7 million for the quarter ended June 30, 2025
Cash, cash equivalents and short-term investments $237 million Up from approximately $145 million as of December 31, 2025
Guidance

The company believes its cash, cash equivalents, and short-term investments will fund current planned clinical milestones and operational investments into late 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What were Perspective Therapeutics (CATX) key financial results for Q2 2026?
Perspective reported a net loss of $26.8 million, or $0.22 per share, for Q2 2026, compared with a net loss of $21.5 million, or $0.29 per share, in Q2 2025. Operating expenses rose mainly from increased research and development.

How much cash does Perspective Therapeutics (CATX) have and what is its runway?
As of June 30, 2026, Perspective held $237 million in cash, cash equivalents, and short-term investments. The company believes this balance is sufficient to fund its current planned clinical milestones and operational investments into late 2027.

What is the status of Perspective Therapeutics’ VMT-α-NET program in neuroendocrine tumors?
VMT-α-NET has treated 76 NETs patients and one meningioma patient as of July 31, 2026. Interim data were consistent with prior findings, and Phase 3 site activation is targeted around year-end 2026, subject to regulatory feedback and protocol finalization.

What progress has Perspective Therapeutics (CATX) made in its VMT01 melanoma program?
Perspective enrolled 27 patients in the VMT01 melanoma trial as of July 31, 2026, across monotherapy and nivolumab combination cohorts. At a 3.0 mCi monotherapy dose, data showed two partial responses among seven treated patients, with generally well-tolerated safety.

How is Perspective Therapeutics expanding its manufacturing network?
The company expects its Chicago metro manufacturing site to complete construction in early 2027 and its Los Angeles metro site in the second half of 2027, expanding to four regional sites to support ongoing studies and the planned VMT-α-NET Phase 3 trial.

What were Perspective Therapeutics’ operating expenses in Q2 2026?
For Q2 2026, research and development expenses were $21.5 million and general and administrative expenses were $7.8 million. Total operating expenses reached $29.3 million, up from $24.3 million in the same quarter of 2025.
0000728387false00007283872026-08-102026-08-10

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2026

 

 

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-33407

41-1458152

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

c/o Perspective Therapeutics, Inc.

2401 Elliott Avenue

Suite 320

 

Seattle, Washington

 

98121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (206) 676-0900

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

CATX

 

NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.02 Results of Operations and Financial Condition.

On August 10, 2026, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026 and providing recent business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Form 8-K”) and is incorporated by reference into this Item 2.02.

 

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

 

Item 8.01 Other Events.

 

Also on August 10, 2026, the Company posted an updated corporate presentation to its website at www.perspectivetherapeutics.com. A copy of the presentation is filed as Exhibit 99.2 to this Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

99.1

 

Press release issued by Perspective Therapeutics, Inc., dated August 10, 2026.

99.2

 

Corporate presentation.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

PERSPECTIVE THERAPEUTICS, INC.

 

 

 

 

Date:

August 10, 2026

By:

/s/ Joel Sendek

 

 

 

Joel Sendek
Chief Financial Officer

 

 

img236230851_0.jpg

Perspective Therapeutics Provides Recent Business Highlights and
Reports 2Q 2026 Results

 

•
Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject to regulatory feedback; sufficient isotope access and manufacturing capacity
•
VMT-α-NET study update accepted for oral presentation at ESMO 2026
•
VMT01 melanoma and PSV359 FAP-α clinical programs continue to advance
•
Approximately $237 million in cash, cash equivalents, and short-term investments as of June 30, 2026; expected to be sufficient to fund current planned clinical milestones and operational investments into late 2027

 

SEATTLE – August 10, 2026 – Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended June 30, 2026.

 

“The team at Perspective is highly energized as we continue to build on the significant clinical progress we're making across our pipeline, prepare for our first Phase 3 study, and advance our flagship Chicago manufacturing facility toward completion,” said Thijs Spoor, Perspective's CEO. “As precision oncology continues to evolve, long-term leadership will require differentiated science, integrated manufacturing, and the ability to reliably deliver these therapies at commercial scale. We are continuing to bring the platform that delivers.”

 

Recent Program Updates

 

We advanced our four-program 212Pb pipeline, expanded our manufacturing network and attracted strong leadership.

 

•
Bamzireotide navoxetan (VMT-α-NET) in SSTR2-positive neuroendocrine tumors (NETs) and meningioma: 76 NETs patients across four cohorts and one meningioma patient treated as of July 31. ASCO 2026 interim data were consistent with prior findings and showed continued deepening of response. Updated data on NETs patients will be presented at ESMO on October 23. By late 2026, all 46 Cohort 2 patients will have had the opportunity for at least 60 weeks of follow-up, which is expected to inform the Phase 3 study design.

 

 

 

Preparing for a Phase 3 study evaluating a proposed cumulative 20 mCi (740 MBq) dose administered in up to four treatments every eight weeks. Additional dose cohorts could provide optionality and opportunity to further define VMT-α-NET’s therapeutic window. Phase 3 site activation targeted around year-end 2026, subject to regulatory feedback and protocol finalization.

 

•
Lapemelanotide zapixetar (VMT01) in MC1R-positive melanoma: 27 patients enrolled across multiple dose cohorts either as monotherapy or in combination with the immune checkpoint inhibitor nivolumab as of July 31. We are focused on a cumulative 9 mCi (333 MBq) dose administered in up to three treatments every eight weeks. Seven patients received this treatment regimen as a monotherapy, and six patients received this dose in combination with nivolumab.

 

Data presented at ASCO 2026 showed two partial responses among seven patients treated with 3.0 mCi monotherapy; safety data from 27 patients showed treatment was generally well tolerated. Six nivolumab combination patients are expected to reach at least 24 weeks of follow-up by late 2026.

 

•
PSV359 in FAP-α-positive solid tumors: 17 patients treated across three dose cohorts as of July 31. Cohort 3 opened and closed during 2Q 2026. The next clinical update is planned in 2027.

 

•
PSV594 in CCK2R-positive solid tumors: Preclinical data and first-in-human biodistribution observations support continued pre-IND development of PSV594.

 

Manufacturing: We expect the Chicago metro site to complete construction in early 2027, followed by the Los Angeles metro site in 2H 2027, expanding the network to four regional sites by the end of 2027. We believe we have sufficient capacity and isotope access to support ongoing studies and the planned VMT-α-NET Phase 3 study.

 

Corporate update: In July 2026, we announced that Paul Lyne, Ph.D. was appointed as Chief Science Officer.

 

Second Quarter 2026 Financial Summary

 

Cash, cash equivalents, and short-term investments as of June 30, 2026, were approximately $237 million as compared to approximately $145 million as of December 31, 2025. We believe our cash, cash equivalents, and short-term investments are sufficient to fund our current planned clinical milestones and operational investments into late 2027.

 

•
Research and development expenses were $21.5 million for the three months ended June 30, 2026, compared to $16.6 million for the three months ended June 30, 2025.



•
General and administrative expenses were $7.8 million for the three months ended June 30, 2026, compared to $7.7 million for the three months ended June 30, 2025.

 

 

 

•
Net loss for the three months ended June 30, 2026, was $26.8 million, or $0.22 per basic and diluted share, compared to a net loss of $21.5 million, or $0.29 per basic and diluted share, for the same period in 2025.

 

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

 

The Company is advancing a portfolio of clinical-stage programs in the U.S., including VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors).

 

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary 224Ra/212Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

 

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

 

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include express or implied statements concerning, among other things, the Company's expectations regarding cash runway; the Company’s manufacturing, distribution and commercialization plans and capabilities; the Company’s clinical and preclinical development plans and the expected timing for the release of additional data from its development programs; the Company’s beliefs that it has sufficient isotope access to support ongoing clinical studies; the Company’s beliefs that its product candidates address certain unmet medical needs; the Company’s expectations regarding regulatory pathways for its product candidates, the Company’s interactions with regulatory agencies and the expected timing thereof; and other statements that are not historical fact.

 

 

 

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s preclinical development plans and clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and development activities; our ability to obtain isotopes pursuant to our supply agreement with the U.S. Department of Energy; economic and market conditions may worsen; regulatory agencies may issue decisions that negatively impact the Company’s product candidates and clinical development plans; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

 

Media and Investor Relations Contact:

 

Perspective Therapeutics IR:

Annie J. Cheng, CFA

ir@perspectivetherapeutics.com

 

 

ENTENTE Network of Companies

Virginia Amann

virginiaamann@ententeinc.com

 

 

Perspective Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(In thousands, except shares and par value data)

 

 

June 30,

 

 

December 31,

 

 

2026

 

 

2025

 

 

 

(unaudited)

 

 

 

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

48,488

 

 

$

30,629

 

Short-term investments

 

 

188,388

 

 

 

114,108

 

Accounts receivable, net of allowance for doubtful accounts: $375 for each period

 

 

269

 

 

 

6

 

Prepaid expenses and other current assets

 

 

4,378

 

 

 

3,646

 

Total current assets

 

 

241,523

 

 

 

148,389

 

Noncurrent assets:

 

 

 

 

 

 

Property and equipment, net

 

 

107,797

 

 

 

76,597

 

Right of use asset

 

 

2,196

 

 

 

1,500

 

Intangible assets, in-process research and development

 

 

40,000

 

 

 

40,000

 

Other assets

 

 

509

 

 

 

486

 

Total assets

 

$

392,025

 

 

$

266,972

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERSʼ EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

29,418

 

 

$

20,511

 

Lease liability

 

 

1,097

 

 

 

623

 

Accrued personnel expenses

 

 

5,972

 

 

 

7,489

 

Note payable

 

 

57

 

 

 

56

 

Total current liabilities

 

 

36,544

 

 

 

28,679

 

Noncurrent liabilities:

 

 

 

 

 

 

Lease liability, net of current portion

 

 

1,269

 

 

 

1,005

 

Note payable, net of current portion

 

 

1,540

 

 

 

1,569

 

Deferred income

 

 

26,600

 

 

 

26,600

 

Deferred tax liability

 

 

1,702

 

 

 

1,702

 

Other noncurrent liabilities

 

507

 

 

386

 

Total liabilities

 

 

68,162

 

 

 

59,941

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholdersʼ equity:

 

 

 

 

 

 

Preferred stock: $0.001 par value; 7,000,000 shares authorized; 5,000,000
 designated Series B convertible; no shares issued

 

 

-

 

 

 

-

 

Common stock: $0.001 par value; 750,000,000 shares authorized; 114,086,092
 and 74,337,990 shares issued

 

 

114

 

 

 

74

 

Additional paid-in capital

 

 

711,785

 

 

 

541,687

 

Accumulated other comprehensive (loss) income

 

 

(221

)

 

 

110

 

Accumulated deficit

 

 

(387,815

)

 

 

(334,840

)

Total stockholdersʼ equity

 

 

323,863

 

 

 

207,031

 

Total liabilities and stockholdersʼ equity

 

$

392,025

 

 

$

266,972

 

 

 

 

Perspective Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

(Dollars and shares in thousands, except for per-share amounts)

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Grant revenue

 

$

81

 

 

$

290

 

 

$

157

 

 

$

632

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

21,544

 

 

 

16,620

 

 

 

42,916

 

 

 

30,952

 

General and administrative

 

 

7,795

 

 

 

7,709

 

 

 

14,780

 

 

 

15,551

 

Total operating expenses

 

 

29,339

 

 

 

24,329

 

 

 

57,696

 

 

 

46,503

 

Operating loss

 

 

(29,258

)

 

 

(24,039

)

 

 

(57,539

)

 

 

(45,871

)

 

 

 

 

 

 

 

 

 

 

 

 

Non-operating income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

2,347

 

 

 

2,159

 

 

 

4,544

 

 

 

4,543

 

Interest and other expense

 

 

(71

)

 

 

(119

)

 

 

(176

)

 

 

(247

)

Other income from a related party

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,400

 

Equity in loss of affiliate

 

 

(1

)

 

 

-

 

 

 

(1

)

 

 

(1

)

Total non-operating income, net

 

 

2,275

 

 

 

2,040

 

 

 

4,367

 

 

 

5,695

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss from continuing operations

 

 

(26,983

)

 

 

(21,999

)

 

 

(53,172

)

 

 

(40,176

)

Net gain from discontinued operations

 

 

197

 

 

 

514

 

 

 

197

 

 

 

514

 

Net loss before income taxes

 

 

(26,786

)

 

 

(21,485

)

 

 

(52,975

)

 

 

(39,662

)

Deferred income tax benefit

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Net loss

 

$

(26,786

)

 

$

(21,485

)

 

$

(52,975

)

 

$

(39,662

)

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

Loss from continuing operations

 

$

(0.22

)

 

$

(0.30

)

 

$

(0.47

)

 

$

(0.55

)

Gain from discontinued operations

 

 

-

 

 

 

0.01

 

 

 

-

 

 

 

0.01

 

Basic and diluted loss per share

 

$

(0.22

)

 

$

(0.29

)

 

$

(0.47

)

 

$

(0.54

)

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares used in
 computing net loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

 

120,651

 

 

 

74,235

 

 

 

112,174

 

 

 

73,301

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on available-
 for-sale securities

 

$

5

 

 

$

(16

)

 

$

(331

)

 

$

54

 

Comprehensive loss

 

$

(26,781

)

 

$

(21,501

)

 

$

(53,306

)

 

$

(39,608

)

 

 

Slide 1

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

Slide 2

 

Slide 3

Engineering the Alpha Advantage in Targeted Oncology

Slide 4

Unlocking New Treatment Options Across Solid Tumors:

Slide 5

Optimizing the Entire System

Slide 6

Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals

Slide 7

Optimizing Structural Chemistry:

Slide 8

Choosing the Right Isotope

Slide 9

Not All ²¹²Pb Programs Are Created Equal

Slide 10

 

Slide 11

Advancing a Theranostic Approach:

Slide 12

Solid Tumors are an Attractive Market for Radiopharmaceuticals

Slide 13

Expanding the Addressable Market

Slide 14

Direct-to-Hospital Delivery through Integrated Isotope Production

Slide 15

Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product

Slide 16

Reaching the Largest Addressable Market with Regional Manufacturing

Slide 17

Advancing a Diverse 212Pb-Based Oncology Portfolio

Slide 18

SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need

Slide 19

VMT-α-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2

Slide 20

Ongoing Phase 1/2a to Establish Broad Therapeutic Window for VMT-α-NET

Slide 21

VMT-⍺-NET: Baseline Patient Characteristics in ASCO 2026 Data Analysis

Slide 22

Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO 2026 Data Analysis

Slide 23

VMT-α-NET Best Response Deepens Over Time

Slide 24

VMT-α-NET Responses Deepen Over Time

Slide 25

VMT-⍺-NET: Durable Disease Control Across All Doses

Slide 26

Spider Plot of Tumor Change Over Time by Patient

Slide 27

Best-in-class Safety Profile1

Slide 28

Blood Creatinine During Follow-up for All Patients Treated (n=68)

Slide 29

VMT-α-NET ’s Compelling Profile Supports Potential Registration Study at Current Dose Level

Slide 30

Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind

Slide 31

VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma

Slide 32

Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma

Slide 33

Preliminary Anti-tumor Activity Observed at 3.0 mCi Dose of VMT01

Slide 34

Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 10% of Patients)

Slide 35

VMT01 Clinical Data Support Further Development

Slide 36

FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential

Slide 37

PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors

Slide 38

Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors

Slide 39

PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent

Slide 40

Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain

Slide 41

 

Slide 42

A Decade of Deliberate, End-to-End Engineering

Slide 43

Built Over a Decade:

Slide 44

 

Slide 45

Abbreviations

Slide 46

APPENDIX

Slide 47

Deep Leadership Across Radiopharmaceutical and Drug Development

Slide 48

NETs Trials

Slide 49

Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment

Slide 50

Refractory Metastatic Melanoma Trials

Slide 51

ICI Combo Rationale: Strong Synergy with VMT01 in Melanoma

Slide 52

Metastatic Melanoma: Confirmed Partial Response after 2 Cycles of [212Pb]VMT01

Slide 53

Perspective’s CCK2R81 in Medullary Thyroid Cancer Compared to FDG and Fluorodopa

Slide 54

 

Slide 55

 

Slide 56

Construct Designed for Better Clinical Outcome

Slide 57

212Pb Uniquely Suited for Combination with Immune Checkpoint Inhibitors

Slide 58

Kinetics Matter: 212Pb Hits Hard and Fast for Strong Activity with Less Systemic Exposure

Slide 59

 

Slide 60

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Press Releases

Other Documents